Kite Pharma

Explore the latest insights on Kite Pharma and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Kite Pharma’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on Kite Pharma and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Kite Pharma's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Novo Nordisk Opens Its Next Chapter With 'Lasting Health Starts Now' Rebrand and 'The Novo Way' Culture – Single 'Novo' Name Signals a Faster, Consumer‑Driven Era
Company

Novo Nordisk Opens Its Next Chapter With ‘Lasting Health Starts Now’ Rebrand and ‘The Novo Way’ Culture – Single ‘Novo’ Name Signals a Faster, Consumer‑Driven Era

Novo Nordisk (NYSE: NVO) today unveiled a corporate rebrand centred on "Lasting Health Starts Now" and the single "Novo" name, together with an updated corporate culture, "The Novo Way", designed…

Sichuan Biokin's HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen

Sichuan Biokin’s HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen

Henlius' Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China's Bone Health Market

Henlius’ Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China’s Bone Health Market

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma

CompanyDeals

Fosun Kairos Secures Greater China Rights to ElpasBio’s AlloJoin for Knee Osteoarthritis

Pregene Partners with Kite to Pioneer Next-Generation In Vivo Therapies
CompanyDeals

Pregene Partners with Kite to Pioneer Next-Generation In Vivo Therapies

Gilead Terminates $2.3 B Collaboration With Kite Pharma Over Off‑the‑Shelf Cell Therapies
CompanyDeals

Gilead Terminates $2.3 B Collaboration With Kite Pharma Over Off‑the‑Shelf Cell Therapies

Kite Pharma Acquires Interius BioTherapeutics for $350 Million to Boost CAR Therapy Platform
CompanyDeals

Kite Pharma Acquires Interius BioTherapeutics for $350 Million to Boost CAR Therapy Platform

CompanyDrug

Gilead’s Kite Subsidiary Reduces CAR T-Cell Therapy Turnaround Time with FDA Approval

CompanyDrug

Fosun Kite’s Yescarta Gains NMPA Approval for Refractory Large B-Cell Lymphoma

CompanyDeals

Kite Pharma’s Yescarta Marketing Rights Transferred to Gilead Sciences K.K. in Japan